Transgene
Blood & Organ Banks · France · 51-200 Employees
View Company Info for Free
Overview
Headquarters
D'andernach Parc D'innovation Cs80166 40...Phone Number
+33 388279100Website
www.transgene.frRevenue
<$5 MillionStock Symbol
TNGIndustry
ZI Rank: 3
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
3
1
2
3
3
About Transgene
Transgene specializes in the design and development of innovative immunotherapies for cancer treatment. Their product portfolio includes personalized therapeutic vaccines like TG4050, oncolytic viruses from the Invir.IO platform, and advanced technologies such as myvac. The company aims to leverage cutting-edge genetic engineering and artificial intelligence to enhance cancer treatment efficacy. Transgene targets patients with various types of cancer, focusing on personalized medicine to improve patient outcomes.Explore more
Transgene Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Transgene your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Transgene recently announced quarterly report
Check out if Transgene is spiking on competitors!
Product Launch: Get notified when Transgene launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Transgene has recently received funding, and reach out quickly before it becomes old news!
Click to see if Transgene had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Transgene has new funding data
Transgene, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Transgene
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
Transgene is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
Transgene is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about Transgene.
Transgene financials insights
Gather financial insights about Transgene, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Debt
$22.4M
2025
Stock/Share Issuance
$121.6M
Transgene Tech Stack
A closer look at the technologies used by Transgene
See more technologies
Most Recent Scoops
Person-Based
Person-Based
Person-Based
Funding
Funding
Person-Based
Transgene News & Media
Transgene’s Combined General Meeting of May 22, 2026
Transgene’s Combined General Meeting of May 22, 2026Availability of Preparatory Documents for the Combined General Meeting of May 22, 2026
Availability of Preparatory Documents for the Combined General Meeting of May 22, 2026Transgene Provides Business and Financial Update for Q1 2026
Transgene Provides Business and Financial Update for Q1 2026Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer
Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer
Read more news
Top Blood & Organ Banks Companies
See more top companies
Frequently Asked Questions Regarding Transgene
Sign Up For FreeTo access detailed company insights
Transgene specializes in the design and development of innovative immunotherapies for cancer treatment. Their product portfolio includes personalized therapeutic vaccines like TG4050, oncolytic viruses from the Invir.IO platform, and advanced technologies such as myvac. The company aims to leverage cutting-edge genetic engineering and artificial in... Read More
